Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 75382E109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Medicxi IV LP
13G
|
16.9% |
1/6/2025
Event 12/27/2024
|
||
| Medicxi IV LP | 16.6% | |||
| Medicxi Co-Invest IV LP | 0.3% | |||
| Medicxi IV GP Limited | 16.9% | |||
| Medicxi Ventures Management (Jersey) Limited | 16.9% | |||
|
TCG Crossover GP II, LLC
13G
|
10.0% |
1/3/2025
Event 12/27/2024
|
||
| TCG Crossover GP II, LLC | 10.0% | |||
| TCG Crossover Fund II, L.P. | 10.0% | |||
| Chen Yu | 10.0% | |||
|
Redmile Group, LLC
13G/A
|
9.9% |
2/14/2025
Event 12/31/2024
|
||
| Redmile Group, LLC | 9.9% | |||
| Jeremy C. Green | 9.9% | |||
| Redmile Biopharma Investments III, L.P. | 5.4% | |||
|
Foresite Capital Fund VI LP
13G
|
9.3% |
12/30/2024
Event 12/23/2024
|
||
| Foresite Capital Fund VI, L.P. | 9.3% | |||
| Foresite Capital Management VI, LLC | 9.3% | |||
| James Tananbaum | 9.3% | |||
| Vanguard Group Inc 13G | 6.3% |
4/30/2025
Event 3/31/2025
|
||
|
Glazer Capital, LLC
13G
|
5.4% |
2/9/2026
Event 2/2/2026
|
||
| Glazer Capital, LLC | 5.4% | |||
| Paul J. Glazer | 5.4% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (8) | ||||
|
Deep Track Capital, LP
13G
|
9.9% |
12/23/2024
Event 12/23/2024
|
||
| Deep Track Capital, LP | 9.9% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 9.9% | |||
| David Kroin | 9.9% | |||
|
RTW Investments, LP
13G
|
8.9% |
5/15/2025
Event 3/31/2025
|
||
| RTW Investments, LP | 8.9% | |||
| Roderick Wong, M.D. | 8.9% | |||
|
Column Group II, LP
13D/A
|
4.9% |
12/23/2024
Event 12/23/2024
|
||
| The Column Group II, LP | 0.6% | |||
| The Column Group II GP, LP | 0.6% | |||
| Ponoi Capital, LP | 0.4% | |||
| Ponoi Management, LLC | 0.4% | |||
| Ponoi Capital II, LP | 0.5% | |||
| Ponoi II Management, LLC | 0.5% | |||
| The Column Group IV, LP | 3.9% | |||
| The Column Group IV-A, LP | 0.1% | |||
| The Column Group IV GP, LP | 4.0% | |||
| The Column Group, LLC | 0% | |||
| Peter Svennilson | 4.9% | |||
| David V. Goeddel | 4.9% | |||
| Tim Kutzkey | 4.8% | |||
|
Perceptive Advisors LLC
13G/A
|
4.5% |
2/14/2025
Event 12/31/2024
|
||
| Perceptive Advisors LLC | 4.5% | |||
| Joseph Edelman | 4.5% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | |||
| BlackRock, Inc. 13G/A | 1.7% |
4/25/2025
Event 3/31/2025
|
||
|
FMR LLC
13G/A
|
0.4% |
2/7/2025
Event 1/31/2025
|
||
| FMR LLC | 0.4% | |||
| Abigail P. Johnson | 0.4% | |||
|
Biotechnology Value Fund L P
13G/A
|
0% |
11/14/2025
Event 9/30/2025
|
||
| Biotechnology Value Fund L P | 0% | |||
| BVF I GP LLC | 0% | |||
| Biotechnology Value Fund II LP | 0% | |||
| BVF II GP LLC | 0% | |||
| Biotechnology Value Trading Fund OS LP | 0% | |||
| BVF Partners OS Ltd. | 0% | |||
| BVF GP Holdings LLC | 0% | |||
| BVF Partners L P/IL | 0% | |||
| BVF Inc/IL | 0% | |||
| Lampert Mark N | 0% | |||
| Orbimed Advisors LLC 13G/A | 0% |
5/15/2026
Event 3/31/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 3 | 2.96 M | $100 M |
| 2025 Q3 | 3 | 2.97 M | $76.7 M |
| 2025 Q2 | 2 | 1.34 M | $10.7 M |
| 2025 Q1 | 95 | 131 M | $160 M |
| 2024 Q4 | 97 | 127 M | $199 M |
| 2024 Q3 | 99 | 29.8 M | $59.9 M |
| 2024 Q2 | 122 | 33.0 M | $101 M |
| 2024 Q1 | 149 | 35.8 M | $322 M |
| 2023 Q4 | 122 | 37.2 M | $925 M |
| 2023 Q3 | 103 | 35.4 M | $589 M |
| 2023 Q2 | 102 | 34.1 M | $637 M |
| 2023 Q1 | 113 | 33.3 M | $611 M |
| 2022 Q4 | 100 | 34.0 M | $673 M |
| 2022 Q3 | 103 | 30.0 M | $721 M |
| 2022 Q2 | 90 | 29.7 M | $543 M |
| 2022 Q1 | 89 | 28.1 M | $618 M |
| 2021 Q4 | 112 | 30.8 M | $1.13 B |
| 2021 Q3 | 120 | 26.4 M | $818 M |
| 2021 Q2 | 134 | 29.1 M | $925 M |
| 2021 Q1 | 91 | 23.6 M | $523 M |
| 2020 Q4 | 93 | 20.4 M | $404 M |
| 2020 Q3 | 71 | 16.8 M | $542 M |
| 2020 Q2 | 56 | 15.1 M | $444 M |
| 2020 Q1 | 40 | 11.8 M | $250 M |
| 2019 Q4 | 29 | 9.17 M | $252 M |